This article has Open Peer Review reports available.
Octreotide-induced thrombocytopenia: a case report
© Rashidi and Rizvi; licensee BioMed Central Ltd. 2011
Received: 4 February 2011
Accepted: 5 July 2011
Published: 5 July 2011
Thrombocytopenia is an extremely rare complication of octreotide therapy and can be life threatening in the setting of esophageal variceal bleeding. We report a case of octreotide-induced reversible thrombocytopenia in a 54-year-old Caucasian man with alcohol-induced cirrhosis and upper gastrointestinal bleeding.
Our patient's platelet count dropped from 155,000/mm3 upon admission to 77,000/mm3 a few hours after initiation of octreotide therapy and stayed low until the drug's administration was discontinued. Significant recovery was achieved quickly after discontinuation of octreotide.
Thrombocytopenia is a rare but potentially serious side effect of octreotide therapy and may complicate esophageal variceal bleeding. Physicians should be vigilant in identifying this potentially serious condition.
Drug-induced thrombocytopenia can complicate esophageal variceal bleeding. Octreotide is a standard treatment in patients with portal hypertension presenting with upper gastrointestinal bleeding. Octreotide-induced thrombocytopenia is a rare condition that has been reported in only two previous cases [1, 2]. Another case is reported herein.
A 54-year-old Caucasian man with a medical history of alcoholic liver disease and grade I esophageal varices presented to our hospital with a one-day history of hematemesis and light-headedness. The patient did not have any comorbidities, and his last alcoholic beverage consumption was three days before admission. His initial vital signs revealed blood pressure of 111/73 mmHg, heart rate of 129 beats/minute, respiratory rate of 22 breaths/minute, and 100% oxygen saturation on room air. His physical examination revealed mild scleral icterus, gynecomastia, ascites, hepatomegaly, and palmar erythema. His relevant laboratory findings were hemoglobin 11.1 g/dL, platelets 155,000/mm3, International Normalized Ratio 1.4, and mean corpuscular volume 89.9 fL/red blood cell.
Thrombocytopenia is an extremely rare side effect of octreotide therapy. To our knowledge, only two cases of this condition have previously been reported in the literature.
In the first case, the platelet count in a 53-year-old man with alcohol-induced cirrhosis dropped immediately after octreotide administration from 144,000/mm3 to 75,000/mm3 and continued to decrease within the next 50 hours to 4000 despite multiple platelet transfusions. After octreotide was discontinued, the patient's platelet count gradually recovered to 28,000/mm3 within about two days. Inadvertent octreotide administration on a subsequent admission resulted in an immediate drop in platelets from 214,000/mm3 to 89,000/mm3. In the second reported case, that of a 42-year-old woman with hepatitis C- and alcohol-induced cirrhosis, the patient's platelet count dropped immediately from 122,000/mm3 to 72,000/mm3 following octreotide administration . In both of these two cases as well as in our patient, octreotide was administered as a standard 50 μg bolus. Interestingly, in all three cases, the immediate drop in platelets was about 50%.
The mechanism of drug-induced thrombocytopenia is most often immunologic , that is, accelerated platelet destruction by drug-dependent antibodies binding to platelet surface glycoproteins . The median recovery time from drug-induced thrombocytopenia following drug discontinuation is thought to be about 1 week .
Physicians need to be aware of the possibility of octreotide-induced thrombocytopenia. Although rare, this condition may significantly worsen esophageal variceal bleeding in patients with cirrhosis. Continued bleeding not explained by anemia and/or clotting factor deficiencies alone should immediately prompt clinical suspicion of octreotide-induced thrombocytopenia. We recommend serial monitoring of not only hemoglobin but also platelets in patients with esophageal variceal bleeding treated with octreotide. On the basis of the limited data available, the level of suspicion for octreotide-induced thrombocytopenia should be high, especially if the immediate drop in platelets is about 50%.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Chisholm S, Gummadi B, Vega KJ, House J: Sandostatin causing reversible thrombocytopenia. Eur J Gastroenterol Hepatol. 2009, 21: 474-475. 10.1097/MEG.0b013e328312180a.View ArticlePubMedGoogle Scholar
- Demirkan K, Fleckenstein JF, Self TH: Thrombocytopenia associated with octreotide. Am J Med Sci. 2000, 320: 296-297. 10.1097/00000441-200010000-00014.View ArticlePubMedGoogle Scholar
- Aster RH, Bougie DW: Drug-induced immune thrombocytopenia. N Engl J Med. 2007, 357: 580-587. 10.1056/NEJMra066469.View ArticlePubMedGoogle Scholar
- Christie DJ, Mullen PC, Aster RH: Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest. 1985, 75: 310-314. 10.1172/JCI111691.View ArticlePubMedPubMed CentralGoogle Scholar
- Pedersen-Bjergaard U, Andersen M, Hansen PB: Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol. 1997, 52: 183-189. 10.1007/s002280050272.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.